Birdsong Research is a network of clinical research sites that are combined to build an Independent Site Network (ISN). The sites are primarily owned by Principal Investigators. Birdsong Research offers Phase II through Phase IV clinical trials across a wide range of therapeutic areas. The Principal Investigators at Birdsong have established long-term relationships within their communities and with pharmaceutical companies.
Industry Size
As of 2023, the North American clinical research market is valued at approximately $20 billion, with projections indicating a compound annual growth rate (CAGR) of 6–8% over the next several years. This growth is driven by increasing investments in R&D, the rising prevalence of chronic diseases, and the ongoing development of innovative therapies..
Industry dynamics Advantages of Independent Site Networks (ISN’s)
As operating expenses rise and study complexities increase, independent research sites are facing growing difficulties as stand-alone businesses. ISN's have distinct advantages, including broader access to clinical trials. These advantages position them more favorably in competing with smaller independent practices. The combination of a robust regulatory environment, technological advancements, and an increasing focus on patient engagement is expected to continue shaping the clinical research landscape.
Diversity FDA Mandates Industry dynamics
As the industry gears up for improved diversity within the patient pool, sites find themselves entrusted with the task of having a proactive response. Birdsong has diverse PI’s and staff. We'll continue to open sites in underserved areas and build on our existing relationships with local communities to assist with recruitment.
Commitment to Community Outreach
The true heroes of clinical research are those who volunteer to advance our understanding of chronic conditions. They are at the heart of everything we do. Partnering with patients, advocates, providers, caregivers, and our communities sets the foundation for cutting-edge scientific discovery.